The FDA is releasing draft guidance on child-resistant packaging statements in the labeling of prescription and over-the-counter drugs. The guidance discusses the information that should be included to support the statements and to help ensure that the labeling is clear, useful, informative and, as much as possible, consistent in content and format, according to a notice slated for publication in Thursday's Federal Register. Comments on the guidance are due by Oct. 2.